The use of herbal medicine in Alzheimer's disease - A systematic review

被引:89
作者
dos Santos-Neto, Leopoldo Luiz
de Vilhena Toledo, Maria Alice
Medeiros-Souza, Patricia
de Souza, Gustavo Almeida
机构
[1] Univ Brasilia, Univ Hosp Brasilia HUB UnB, Ctr Clin Med, Gen Internal Med Ctr, BR-70919970 Brasilia, DF, Brazil
[2] Univ Brasilia, Univ Hosp Brasilia, Dept Geriatr, Gen Internal Med Ctr, BR-70919970 Brasilia, DF, Brazil
[3] Univ Brasilia, Sch Pharm, Dept Hlth Sci, BR-70919970 Brasilia, DF, Brazil
关键词
Alzheimer's disease; cognitive impairment; dementia; elderly; herbs; randomized clinical trial; systematic review;
D O I
10.1093/ecam/nel071
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
The treatments of choice in Alzheimer's disease (AD) are cholinesterase inhibitors and NMDA-receptor antagonists, although doubts remain about the therapeutic effectiveness of these drugs. Herbal medicine products have been used in the treatment of Behavioral and Psychological Symptoms of Dementia (BPSD) but with various responses. The objective of this article was to review evidences from controlled studies in order to determine whether herbs can be useful in the treatment of cognitive disorders in the elderly. Randomized controlled studies assessing AD in individuals older than 65 years were identified through searches of MEDLINE, LILACS, Cochrane Library, dissertation Abstract (USA), ADEAR (Alzheimer's Disease Clinical Trials Database), National Research Register, Current Controlled trials, Centerwatch Trials Database and PsychINFO Journal Articles. The search combined the terms Alzheimer disease, dementia, cognition disorders, Herbal, Phytotherapy. The crossover results were evaluated by the Jadad's measurement scale. The systematic review identified two herbs and herbal formulations with therapeutic effects for the treatment of AD: Melissa officinalis, Salvia officinalis and Yi-Gan San and BDW (Ba Wei Di Huang Wan). Ginkgo biloba was identified in a meta-analysis study. All five herbs are useful for cognitive impairment of AD. M. officinalis and Yi-Gan San are also useful in agitation, for they have sedative effects. These herbs and formulations have demonstrated good therapeutic effectiveness but these results need to be compared with those of traditional drugs. Further large multicenter studies should be conducted in order to test the cost-effectiveness of these herbs for AD and the impact in the control of cognitive deterioration.
引用
收藏
页码:441 / 445
页数:5
相关论文
共 30 条
[1]   Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease:: a double blind, randomized and placebo-controlled trial [J].
Akhondzadeh, S ;
Noroozian, M ;
Mohammadi, M ;
Ohadinia, S ;
Jamshidi, AH ;
Khani, M .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2003, 28 (01) :53-59
[2]   Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease:: a double blind, randomised, placebo controlled trial [J].
Akhondzadeh, S ;
Noroozian, M ;
Mohammadi, M ;
Ohadinia, S ;
Jamshidi, AH ;
Khani, M .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2003, 74 (07) :863-866
[3]   Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia:: The results of a double-blind, placebo-controlled trial with Melissa [J].
Ballard, CG ;
O'Brien, JT ;
Reichelt, K ;
Perry, EK .
JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (07) :553-558
[4]  
Bentham P, 2004, LANCET, V363, P2105
[5]  
BIRKS JS, 2004, COCHRANE LIB
[6]  
Carnat A., 1998, Pharmaceutica Acta Helvetiae, V72, P301
[7]   Tolerability and efficacy of valerian/lemon balm in healthy volunteers (a double-blind, placebo-controlled, multicentre study) [J].
Cerny, A ;
Schmid, K .
FITOTERAPIA, 1999, 70 (03) :221-228
[8]   Practice parameter: Management of dementia (an evidence-based review) - Report of the Quality Standards Subcommittee of the American Academy of Neurology [J].
Doody, RS ;
Stevens, JC ;
Beck, C ;
Dubinsky, RM ;
Kaye, JA ;
Gwyther, L ;
Mohs, RC ;
Thal, LJ ;
Whitehouse, PJ ;
DeKosky, ST ;
Cummings, JL .
NEUROLOGY, 2001, 56 (09) :1154-1166
[9]   Economic evaluation of donepezil in moderate to severe Alzheimer disease [J].
Feldman, H ;
Gauthier, S ;
Hecker, J ;
Vellas, B ;
Hux, M ;
Xu, Y ;
Schwam, EM ;
Shah, S ;
Mastey, V .
NEUROLOGY, 2004, 63 (04) :644-650
[10]   Cost effectiveness of memantine in moderately severe to severe Alzheimer's disease -: A Markov model in Finland [J].
François, C ;
Sintonen, H ;
Sulkava, R ;
Rive, B .
CLINICAL DRUG INVESTIGATION, 2004, 24 (07) :373-384